DPYD

DPYD Sequencing Identifies More Clinically Relevant Variants as Compared to Targeted Genotyping

DPYD deficiency — exhaustive sequencing vs targeted genotyping to identify patients at risk of fluoropyrimidine toxicity

Importance of and Strategies for Implementing DPYD Testing to Prevent Severe Fluoropyrimidine Chemotherapy Toxicity in Health Care Systems

DPYD testing implementation before fluoropyrimidines — 2025 FDA recommendations and institutional deployment strategies

Integrating Somatic and Germline Pharmacogenomics for Therapeutic Decisions in Precision Oncology.

Pharmacogenomics in precision oncology — somatic + germline integration in 10,302 cancer patients (TCGA)

Importance of and Strategies for Implementing DPYD Testing to Prevent Severe Fluoropyrimidine Chemotherapy Toxicity

Severe fluoropyrimidine toxicity (5-FU, capecitabine, tegafur) — neutropenia, severe mucositis, death

DPYD c.85 T > C, DPYD c.496 A>G, and DPYD c.2194 G>A and severe toxicity to fluoropyrimidines in PREPARE and Alpe-DPD trials. An original study and meta-analysis.

Severe fluoropyrimidine-related toxicity

Dihydropyrimidine Dehydrogenase Genotype-Phenotype Correlations in Plasma and Peripheral Blood Mononuclear Cells.

Severe 5-fluorouracil toxicity due to DPD deficiency

The variant c.2766+3A>T in DPYD leads to exon 21 skipping and is associated with DPD deficiency and severe fluoropyrimidine toxicity.

Dihydropyrimidine dehydrogenase deficiency and fluoropyrimidine toxicity

DPYD polymorphisms in Native populations from the Brazilian Amazon: the absence of the variants in currently recommended clinical genotyping panels

Fluoropyrimidine toxicity — DPYD variants in indigenous populations

DPYD and UGT1A1 Genotype-Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant-Specific Impact on Treatment Intensity and Toxicity.

Fluoropyrimidine and irinotecan toxicity

Considerations for the clinical implementation of DPYD and UGT1A1-guided chemotherapy

DPYD and UGT1A1 — clinical implementation of pharmacogenomic testing guiding fluoropyrimidine and irinotecan chemotherapy

Clinical response to capecitabine in a DPYD*2A homozygous patient: Case report and therapeutic guidance.

Complete DPD deficiency (DPYD2A homozygous) — ultra-low-dose capecitabine

Cost-effectiveness of DPYD genotyping prior to fluoropyrimidine-based treatment for colorectal cancer in Wales.

Colorectal cancer — fluoropyrimidine toxicity

Dihydropyrimidine dehydrogenase (DPYD) genetic testing and treatment with 5-fluoropyrimidines in cancer patients

Cancer — prevention of 5-fluoropyrimidine toxicity

Genotype-Phenotype Predictive Gap in Pre-Emptive Screening of DPD Deficiency: Improving Sensitivity

Dihydropyrimidine dehydrogenase deficiency and fluoropyrimidine toxicity

Association Between DPYD Gene Variants and Severe Fluoropyrimidine-Related Toxicity in Asian and African Populations: A Systematic Review.

Severe fluoropyrimidine toxicity in solid tumors

Implementation and early outcomes of an in-house DPYD genotyping program for fluoropyrimidine safety.

Fluoropyrimidine toxicity in solid tumours

Characterization of DPYD pharmacogenetic variation in Mexican patients with gastrointestinal malignancies.

Fluoropyrimidine toxicity in gastrointestinal cancers

Prevalence and clinical impact of the uncommon DPYD c.257C>T (Pro86Leu) variant in a multiethnic cohort receiving fluoropyrimidine therapy.

Severe fluoropyrimidine toxicity

DPYD Genotyping of Patients with Fluoropyrimidine Treatment: Results of Protocol Implementation and Outcomes of Patients Carrying Unusual DPYD Variants

Fluoropyrimidine toxicity

Functional characterization of rare DPYD variants identified in 8,380 Japanese individuals: implications for 5-fluorouracil metabolism.

DPD deficiency and fluoropyrimidine toxicity

Allelic Variants of the DPYD Gene in Russian Patients with Cancer: The Results of Exome Sequencing.

DPYD variants and fluoropyrimidine toxicity risk (Russian cohort)